# INSIGNA (NCT03793179)

> Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03793179
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
- Interventions: Biospecimen Collection; Carboplatin; Computed Tomography; Magnetic Resonance Imaging; Pembrolizumab; Pemetrexed; Positron Emission Tomography
- Enrollment: 600
- Primary outcome: Overall survival (OS)

## Indexed commentary on INSIGNA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 27
- YouTube: 5
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=insigna-nct03793179

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03793179", "email": "<work email>"}; the inbox owner confirms by the emailed link.